@CURCMB

Carolina Urologic Research Center (CURC), under the direction of Dr. Neal Shore is a research arm of Grand Strand Urology in Myrtle Beach, SC

 Myrtle Beach, SC
carolinaurologicresearchcenter.com
Joined May 2022
  • Tweets24
  • Following98
  • Followers65
8Media
⚡On #ClinicalTrialsDay—the only global campaign dedicated to recognizing & championing #ClinicalResearch professionals—we celebrate YOU! Watch this message of gratitude, tag your colleagues & share! 🎉 Our #CTD2025 Sponsors: @advarra @sanofi @thermofisher @velocitycr @Merck
3
3
282
Dr. @LaurenCooleyUro and clinical research coordinator, Ashley Burns RN, speak today at Duravelo-2 Investigator Meeting in Boston regarding their expertise on the phase 2/3 Duravelo-2/Bicycle Toxin clinical trial currently enrolling at Carolina Urologic Research Center
1
187
Dr. David Rich and Clinical Research Coordinator Ashley Burns attended training this weekend in Minneapolis for the new Vapor 2 Study from Francis Medical. CURC is excited to offer this focal therapy for intermediate risk prostate cancer soon! @AUCStoneGuy @FrancisMedical
1
1
8
664
Dr. Abhi @shekabhishek and Dr. Shore walking today with our CURC team in the BCAN Walk to End Bladder Cancer. We are honored to walk for our patients! @BladderCancerUS #bladderwalk #noonewalksalone
1
6
1,379
CURC was proud to sponsor the Zero Prostate Cancer Tee Off event at Top Golf and help to raise $31,000 to zero out prostate cancer!
1
132
Extended Darolutamide Demonstrates Long-term Safety, Clinical Benefit in Nonmetastatic CRPC @CURCMB @AmerUrological #AUA23 #pcsm ow.ly/ntye50O27bL

Extended Darolutamide Demonstrates Long-term Safety, Clinical Benefit in Nonmetastatic CRPC |...

Darolutamide given in an extended duration was linked with long-term clinical benefit and safety in patients with nonmetastatic castration-resistant prostate cancer.

onclive.com
3
2
1,109
Two of the Most Read Articles of 2022: (#3) @tumastologo1 et al. w/ @Invitae ascopubs.org/doi/full/10.120… @JCOGO_ASCO & (#5) Esplin et al. w/ @DanaFarber @cityofhope @MayoClinic @CURCMB @Invitae ascopubs.org/doi/full/10.120… @JCOPO_ASCO #patient #access #universal #germlinetesting

Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing...

PURPOSETo report on pathogenic germline variants detected among individuals undergoing genetic testing for hereditary breast and/or ovarian cancer (HBOC) from Latin America and compare them with...

ascopubs.org
JCO Precision Oncology
@JCOPO_ASCO14 Feb 2023
⭐ #JCOPO published outstanding articles in 2022. Check out the top 5! ➡️ fal.cn/3vS6d Authors include: @SalemGIOncDoc @alexdrilon @EdEsplin
2
4
498
PROCLAIM...supports #universal #genetictesting for #prostatecancer #patients [to] eliminate barriers to #precisiontherapy, optimize #patient outcomes & accelerate equitable access to care - #DrNealShore @CURCMB ir.invitae.com/news-and-even… ascopubs.org/doi/full/10.120… @JCOPO_ASCO @ASCO
4
1
7
"#Universal #Germline #GeneticTesting for Hereditary Cancer Syndromes in #Patients With Solid Tumor #Cancer" @judygarber5 @DrHQRana @DanaFarber @HHampel1 @cityofhope @J_Samadder @MayoClinic #DrNealShore @CURCMB @Invitae in @JCOPO_ASCO @ASCO ascopubs.org/doi/abs/10.1200…
20
4
59
In case you have missed #BCANTT22, @pjhensley11 has some wonderful summaries of some of the sessions at the conference. Click here to read them: urotoday.com/conference-high… #bladdercancer
1
6
8
.@BenMironMD @FoxChaseCancer brainstorming how to integrate urine and blood ctDNA into improving trials that help patients with localized #bladdercancer retain their bladder yet still be cured. One of the best highlights of this thinktank #BCANTT22!
This Post is from an account that no longer exists. Learn more
3
11
Can’t wait for next year!
Dr. Bishoy M. Faltas@FaltasLab5 Aug 2022
It was great to see everyone at #BCANTT22, looking forward to welcoming you all #BCANTT23 in DC @BladderCancerUS
2
Final session of #BCANTT22. What makes this meeting special is the star-studded panel that includes a #PatientAdvocate, and the discussion starts and ends with the patient voice. Thank you for an amazing meeting @BladderCancerUS!
1
5
37
This was a great panel and end to #BCANTT22. Our site currently offers 2 bladder-soaring trials for MIBC. Very interesting to hear more insight and research on this topic!
Bladder Cancer Advocacy Network
@BladderCancerUS5 Aug 2022
#BCANTT22 panel on Organ-Sparing Management for Muscle-Invasive #Bladdercancer with ⁦@BenMironMD⁩
4
#BCANTT22
10
Medical Director/Principal Investigator Dr. Neal Shore and RN/Clinical Research Coordinator Ashley Burns of CURC attending the #BCANTT22 conference
1
6
Today at #BCANTT22, BCAN announced its first-ever Translational Clinical Trial Award (TCTA) to support patient-oriented research to transform #bladdercancer - up to $3M in funding over 3 years. Click for more detailed about this exciting announcement: bcan.org/bladder-cancer-advo…
1
10
3
21
Really enjoyed this discussion on the sequencing of therapies for Metastatic UC. Great insight from the presenters and attendees.
Shilpa Gupta
@shilpaonc4 Aug 2022
Happening now! @kalasri3 kicking off our session on Sequencing therapies sun mUC #BCANTT22 @BladderCancerUS @bcan_chisolm@PGrivasMDPhD @DrOmarMian @ERPlimackMD Lot of interesting discussion about cisplatin, platinum ineligibility, sequencing, biomarkers and case discussion!
3
Some observations after ~16 yrs at @BladderCancerUS #BCANTT22 The science gets better each year 🧬 Young investigator # exponentially up 🔬✅ Patients’ voice 👍 Funding interest is ⬆️⬆️ … the # of folks wearing suits is at all time high (despite @bcan_chisolm efforts 🙃)
1
12
39
It’s time to focus on sexual function of women w/ #bladdercancer undergoing cystectomy @Svet_MD leading the charge w/ @BladderCancerUS YIA multi-institutional cohort study #BCANTT22
1
10
1
58
Load more